口服普萘洛尔治疗婴幼儿头面部血管瘤  

Therapeutic efficacy of Oral administration of propranolol in infantile with face or head hemangioma

作　　者：肖强[1] 李勤[1] 齐向东[1] 余文林[1] 吴燕虹[1] 张斌[1] 熊杰[1] 彭丽霞[1] 

机构地区：[1]广州军区广州总医院整形外科,510010

出　　处：《中华小儿外科杂志》2012年第9期644-646,共3页Chinese Journal of Pediatric Surgery

摘　　要：目的探讨口服普萘洛尔治疗婴幼儿头面部增生期血管瘤的临床效果。方法将婴幼儿头面部增生期血管瘤患儿90例，分为：口服普萘洛尔治疗组（普萘洛尔组）45例，口服强的松治疗组（强的松组）45例，随诊1～24个月。结果普萘洛尔组总有效率为97．78％（44／4．5），强的松组总有效率为77．78o／4（35／45），普萘洛尔组疗效优于强的松组，且差异有统计学意义（P〈0．05）。各组均未出现严重并发症。结论口服普萘洛尔治疗婴幼儿头面部增生期血管瘤方法简单、疗效可靠、不良反应小，可作为婴幼儿血管瘤增生期的临床一线治疗方法。Objective To investigate the clinical efficacy of oral administration of propranolol in infantile associated with head or neck hemangiomas. Methods 90 infants associated with advanced stage of hemangiomas were divided into 2 groups randomly. 45 cases were orally administrated with optimal dose of propranolol and dexamethasone in each group. Both doses in them were based on the weight of patients. All patients were evaluated clinical effects after 1-24 months of follow-up. Results The total effective rate in propranolol group was 97. 78% and was superior to dexamethasone group （77. 78%）. No severe complications was noted in both groups. Conclusions Oral administration of propranolol is an easy and reliable way to treat infantile with advanced stage of head or neck hemangiomas with less side effects, and can be as effective reagents for such patients.

关 键 词：普萘洛尔 血管瘤 头部 面部 

分 类 号：R739.5[医药卫生—肿瘤]